Tissue factor pathway inhibitor 2 as a serum biomarker for endometrial cancer: a single-center retrospective study

Endometrial cancer is the most common gynecological malignancy; however, there is no useful blood diagnostic biomarker. This study aimed to determine the utility of tissue factor pathway inhibitor 2 (TFPI2), a biomarker of ovarian cancer, as a diagnostic marker for endometrial cancer. We examined se...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2024-08, Vol.24 (1), p.1058-11
Main Authors: Uomoto, Mari, Ota, Yukihide, Suzuki, Yukio, Yumori, Asuna, Narimatsu, Hiroto, Koizume, Shiro, Sato, Shinya, Nakamura, Yoshiyasu, Myoba, Shohei, Ohtake, Norihisa, Saji, Haruya, Miyagi, Etsuko, Miyagi, Yohei
Format: Article
Language:English
Subjects:
Adult
Aged
Antigens
Biomarkers
Biomarkers, Tumor - blood
CA-125 Antigen - blood
Cancer
CEA (Oncology)
Chemical industry
Clinical trials
Comparative analysis
Development and progression
Diagnosis
Discrepancy
Endometrial cancer
Endometrial Neoplasms - blood
Endometrial Neoplasms - diagnosis
Endometrial Neoplasms - pathology
Endometrium
Female
Glycoproteins - blood
Health aspects
Health care
Herbicides
Histology
Humans
Immunohistochemistry
Malignancy
Measurement
Medical prognosis
MicroRNAs
Middle Aged
Neoplasm Staging
Oncology, Experimental
Ovarian cancer
Pesticides industry
Physiological aspects
Prognosis
Prognostic factor
Protease inhibitors
Retrospective Studies
Serum biomarker
Surgery
TFPI2
Tissue factor
Tumor markers
Tumors
Uterine cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Endometrial cancer is the most common gynecological malignancy; however, there is no useful blood diagnostic biomarker. This study aimed to determine the utility of tissue factor pathway inhibitor 2 (TFPI2), a biomarker of ovarian cancer, as a diagnostic marker for endometrial cancer. We examined serum TFPI2 levels in patients with endometrial cancer (n = 328) compared to those in healthy controls (n = 65) and evaluated the performance of serum TFPI2 levels as a diagnostic marker. We investigated the clinicopathological characteristics of patients with TFPI2-negative and TFPI2-positive endometrial cancer. Using immunohistochemistry (IHC), we examined TFPI2 expression in tumor tissues of 105 patients with type II endometrial carcinoma and evaluated the correlation between serum and tissue TFPI2 positivity. Patients with endometrial cancer had significantly higher serum TFPI2 levels than controls (196.7 pg/mL vs. 83.3 pg/mL; p 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-024-12827-0